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COVID- 19 pandemic dramatically impacted transplantation landscape. Scientific soci-
eties recommend against the use of donors with active SARS- CoV- 2 infection. Italian 
Transplant Authority recommended to test recipients/donors for SARS- CoV- 2- RNA 
immediately before liver transplant (LT) and, starting from November 2020, grafts 
from deceased donors with active SARS- CoV- 2 infection were allowed to be con-
sidered for urgent- need transplant candidates with active/resolved COVID- 19. We 
present the results of the first 10 LTs with active COVID- 19 donors within an Italian 
multicenter series. Only two recipients had a positive molecular test at LT and one 
of them remained positive up to 21 days post- LT. None of the other eight recipients 
was found to be SARS- CoV- 2 positive during follow- up. IgG against SARS- CoV- 2 at LT 
were positive in 80% (8/10) of recipients, and 71% (5/7) showed neutralizing antibod-
ies, expression of protective immunity related to recent COVID- 19. In addition, testing 
for SARS- CoV- 2 RNA on donors’ liver biopsy at transplantation was negative in 100% 
(9/9), suggesting a very low risk of transmission with LT. Immunosuppression regimen 
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1  |  INTRODUC TION
The coronavirus disease 2019 (COVID- 19) pandemic dramatically 
impacted the landscape of organ donation and transplantation in 
Europe and United States.1,2
Severe acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) 
utilizes for cellular entry the angiotensin converting enzyme 2 which 
is mostly expressed in lungs, explaining why the respiratory system 
involvement predominates.3 Nevertheless, organ dysfunction be-
yond the lungs has been described as well, in particular liver injury 
was seen in 14%– 53% of patients due to infection of liver cells, drug- 
induced or within a systemic inflammatory syndrome.4
European and American scientific societies recommend against 
the use of organs from donors with active SARS- CoV- 2 infec-
tion and recommend donor SARS- CoV- 2 screening to prevent 
inadvertent positive organ transplant.5,6 On the other hand, the 
Organ Procurement and Transplantation Network Ad Hoc Disease 
Transmission Advisory Commitee reviewed published literature until 
April 2021 and suggested that the decision to recover organs from 
donors with active COVID- 19 should evaluate the recipient's risk 
mortality and the risk of transmission to surgical teams.7 The pro- con 
debate is going on, waiting for real- life data.8,9 The current recom-
mendations are based on the assumptions that (1) SARS- CoV- 2 could 
be transmitted to the recipient through organ transplantation, (2) it 
could result in severe manifestations in immunosuppressed patients, 
(3) there are only limited targeted treatment options, and (4) long- 
term allograft outcomes related to the use of such organs are largely 
unknown. So far, 11 SARS- CoV- 2 infected donors (active COVID- 19), 
diagnosed after donation, without transmission to 18 different re-
cipients have been published (one living liver donor, one platelet 
transfusion, two allogenic hematopoieticstem cell transplantations, 
and 13 kidneys and one liver from deceased donors).7,10- 14
Unfortunately, three cases of proven SARS- CoV- 2 transmission 
from lung donor to recipient (despite negative donor upper respira-
tory tract testing) have been reported.7,14,15 However, donor- derived 
infection with viruses that infect the respiratory tract has been al-
ready described in the past and almost exclusively detected in lung 
recipients.16 These risks must be balanced against the lifesaving ben-
efit of organ transplantation to patients who might otherwise have 
limited opportunities for transplant, due to disease acuity, limited 
matches related to blood type or sensitization, and may not survive 
to receive another organ from a non- infected donor. Furthermore, 
wait- listed patients are at risk for COVID- 19 due to multiple co- 
morbid conditions and frequent healthcare contacts.
Italy has been the first European country to face the se-
vere COVID- 19 pandemic since February 2020 and our National 
Healthcare System is enduring a tremendous pressure. In order not 
to compound the outbreak lethality with risking the lives of patients 
who need a lifesaving liver transplant (LT), all transplant Centers re-
mained open, although a reduction in the activity was noted due 
to donor shortage.17 Italian Transplant Authority (Centro Nazionale 
Trapianti, CNT) recommended to test all recipients and donors for 
SARS- CoV- 2 RNA immediately before LT and, to expand the donor 
pool, starting from November 2020 grafts from deceased donors 
with active SARS- CoV- 2 infection were allowed to be considered for 
urgent- need transplant candidates, who were known to be SARS- 
CoV- 2 positive or with past COVID- 19, and were able to sign an in-
formed consent.
As scanty data exist regarding the safety of transplanting organs 
recovered from donors with active COVID- 19, we present here the 
results of the first 10 consecutive LT cases with such donors within 
an Italian multicenter (five centers involved) national series.
2  |  MATERIAL S AND METHODS
2.1  |  Study period
We enrolled patients from November 20, 2020, to February 8, 2021. 
Follow- up was closed on July 18, 2021.
2.2  |  Definitions
The Organ Procurement and Transplantation Network Ad Hoc 
Disease Transmission Advisory Committee7 defined active COVID- 19 
an immunocompetent donor with a history of confirmed COVID- 19, 
less than 21 days from the date of disease onset and SARS- CoV- 2 
detected in a respiratory sample or an asymptomatic donor with 
detection of SARS- CoV- 2 in a respiratory sample without a reliable 
remained unchanged, according to standard protocol. Despite the small number of 
cases, these data suggest that transplanting livers from donors with active COVID- 19 
in informed candidates with SARS- CoV- 2 immunity, might contribute to safely in-
crease the donor pool.
K E Y W O R D S
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donor evaluation, donors and donation: donor- derived infections, ethics and public policy, 
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history to determine the timeline of past symptoms of COVID- 19; 
mild COVID- 19 as detection of SARS- CoV- 2 in a respiratory sample 
in subjects with symptoms consistent with COVID- 19 infection who 
did not require oxygen supplementation or inpatient hospitaliza-
tion for COVID- 19; severe COVID- 19 as detection of SARS- CoV- 2 
in a respiratory sample in subjects with symptoms consistent with 
COVID- 19 infection who required oxygen supplementation or inpa-
tient hospitalization for COVID- 19.
2.3  |  Donors
The donors underwent detection of SARS- CoV- 2 nucleic acid in 
nasopharyngeal swabs (NPS) or bronchoalveolar lavage (BAL) and 
detection of IgG anti SARS- CoV- 2 at recovery. According to clinical 
history, they underwent SARS- CoV- 2 RNA evaluation before recov-
ery, as reported in Table 1.
SARS- CoV- 2 nucleic acid was tested on liver biopsy collected at 
back- table, before graft reperfusion.
2.4  |  Recipients
All recipients were tested at LT for SARS- CoV- 2 nucleic acid in NPS 
and/or in BAL and for IgG anti- SARS- CoV- 2. For the first month after 
LT, they underwent weekly evaluation of SARS- CoV- 2 RNA in NPS 
and SARS CoV- 2 IgG (Table 1 and Supportive Table S1).
In Turin LT Center, starting from November 20, 2020, all recipi-
ents were also tested for SARS- CoV- 2 IgG at registration on the LT 
waiting list.
2.5  |  SARS- CoV- 2 tests
IgG antibodies against SARS- CoV- 2 have been tested with Liaison® 
SARS- CoV- 2 anti- S1/S2 IgG test (DiaSorin, Saluggia Italy), cut- off 
value for positivity of 15 AU/ml. Sensitivity and specificity of the 
test is 75.6% and 100%, respectively18; the positive and negative 
agreement with Plaque Reduction Neutralization Test is 94.4% and 
97.8%, respectively, according to the manufacturer; or ARCHITECT® 
SARS- CoV- 2 IgG immunoassay (Abbott, Milan, Italy) with a cut- off 
value for positivity of 1.4 AU/ml. Sensitivity and specificity of the 
test is 70% and 100% respectively.19
Neutralizing antibody (NT- Abs) against SARS- CoV2 test was per-
formed in BSL- 3 suite adapting an in- house previously reported neu-
tralization assay.20 Vero E6 cells were seeded at 2 × 104 cells/well 
concentration in a 96- well microtitre plate, 24 hours before the assay. 
Briefly, 50 µl of plasma samples from each patient were serially diluted 
(from 1:10 to 1:5120) in sextuplicate and mixed with 100 median tissue 
culture infectious doses (TCID50) of SARS- CoV- 2 virus (human strain 
VR PV10734, gently provided by INMI L. Spallanzani). After 1 hour 
incubation at 37°C, plasma and virus were transferred to Vero E6 mi-
croplates. Cells were incubated at 37°C in 5% CO2, for 5 days prior to 
microscopic evaluation of the cytopathic effect (CPE). Neutralization 
titer was determined by the highest plasma dilution showing a 50% 
reduction of CPE and evaluated according to the Reed- Muench for-
mula.21 Positive and negative controls were included in all test runs. 
The recipient 9 was tested for NT- Abs, as recently published.22
SARS- CoV- 2 nucleic acid was detected in NPS or BAL by using di-
rect real- time PCR assay for in vitro qualitative detection: Simplexa® 
COVID- 19 Direct (DiaSorin) or Xpert® Xpress SARS- CoV- 2 (Cepheid 
Europe SAS) or GeneFinder™ COVID- 19 Plus RealAmpKit (OSANG 
Healthcare Co. Ltd.). SARS- CoV- 2 nucleic acid was detected in 
liver tissue by using Simplexa® COVID- 19 Direct (DiaSorin) or 
GeneFinder™ COVID- 19 Plus RealAmpKit (OSANG Healthcare Co. 
Ltd.).
2.6  |  Liver transplant and study procedures
During organ procurements and LT, the liver teams used protec-
tive equipment such as filtering face masks (NK- 92, N95, FFP2, 
and FFP3), eye goggles and standard gloves and gowns. The organ 
procurements were performed using standard technique, and 
the livers were preserved in cold storage with Celsior solution. 
Immunosuppression regimen was detailed for each patient.
By Italian law, Regional Transplantation Centers are the custodi-
ans of donor/recipient biomedical data also for research purposes. 
All study procedures complied with the ethical standards of the 
2000 Declaration of Helsinki and the Declaration of Istanbul 2008.
3  |  RESULTS
3.1  |  Donors
During the study period we enrolled 10 brain- dead donors (Table 1) 
with a median age of 61 years (range 14– 82), median body mass 
index 24.5 kg/m2 (range 20– 29), donor risk index 2.0 (range 1.11– 
2.41). All the subjects were affected by active COVID- 19: five do-
nors were SARS- CoV- 2 RNA positive in NPS with pneumonia (four 
patients) or anosmia/fever (one patient) within 21 days before organ 
recovery; the five remaining donors tested SARS- CoV- 2 RNA posi-
tive in BAL at recovery without a reliable history to determine the 
timeline of past symptoms of COVID- 19. At recovery, IgG anti SARS- 
CoV- 2 tested negative in seven of eight donors and SARS- CoV- 2 
RNA on liver biopsy was negative in nine of nine (Table 1).
3.2  |  Recipients
The median recipient age was 56 years (range 1– 70); median body 
mass index 25 kg/m2 (range 16– 34); half of them were affected by 
alcohol cirrhosis and 40% by hepatocellular carcinoma. The median 
Model for End Stage Liver Disease score at LT was 13 (range 7– 35) 
and patient 1 had a Pediatric End Stage Liver Disease score of 29.
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Five patients had a history of severe COVID- 19 which required 
inpatient hospitalization, with oxygen supplementation (one non- 
invasive ventilation) and lung CT scan showing pneumonia in three 
of them; only patient 9 was treated with heparin and steroids; none 
of them received remdesevir. Three patients (1, 7, and 8) were af-
fected by mild COVID- 19 (with fever, anosmia, fatigue), which did 
not require oxygen supplementation or hospitalization. These eight 
patients underwent LT after a median time of 46 days (range 22– 85) 
from the first available SARS- CoV- 2 RNA positive test (Table 1).
Patients 4 and 6 tested IgG anti- SARS- CoV- 2 positive (titer 47 
and 103 AU/ml, respectively) with negative SARS- CoV- 2 RNA on 
NPS at registration on the LT waiting list (1 day and 47 days before 
LT, respectively); both of them reported an undefined history of fa-
tigue in the previous month, but they did not perform at that time a 
SARS- CoV- 2 RNA test. At LT their IgG titres persisted positive (48.5 
and 110 AU/ml, respectively) with persistent negative RNA on NPS.
SARS- CoV- 2 RNA in NPS at LT was negative in all candidates 
except for patient 5 who was indeterminate in NPS and positive in 
BAL, and patient 9 who was positive in NPS. Both patients tested 
RNA positive for the first time one month before LT and became 
persistently negative at NPS starting from postoperative day (POD) 
28. All the others tested SARS- CoV- 2 RNA negative on weekly NPS 
during the first month after LT (Supportive Table S1). None of the LT 
recipients developed COVID- 19 symptoms.
At LT, 8 of 10 patients tested SARS- CoV- 2 IgG positive. Case 1 
(a pediatric patient who was affected by Wiedemann- Steiner syn-
drome and combined immunodeficiency with low immunoglobulin 
levels needing replacement therapy) and case 8 were IgG negative 
at LT and during the first- month follow- up. Case 4 lost IgG positiv-
ity starting from POD7. NT- Abs against SARS- CoV- 2 were evaluated 
in seven patients at LT and tested positive in five of them (71%) 
(Supportive Table S1).
None of the enrolled subjects received anti- SARS- CoV- 2 vacci-
nation during the study period.
Immunosuppression was based on basiliximab induction and tac-
rolimus for two patients (1 and 7), steroids, mycophenolate mofetil 
and tacrolimus for seven patients and tacrolimus plus everolimus in 
the remaining one (9).
The median post- LT hospital length of stay was 16 days (range 
7– 140).
After a median follow- up of 221 days (range 75– 239), patient 
9 died on POD75 due to sepsis caused by multidrug- resistant 
Acinetobacter baumannii; alpha- fetoprotein serum levels of patient 
3 were found to be elevated at 3- month follow- up and chest/abdo-
men CT scan showed lung nodular areas which are currently treated 
with everolimus and sorafenib. The liver function of the nine surviv-
ing patients is satisfactory.
4  |  DISCUSSION
The COVID- 19 pandemic dramatically impacted the landscape of 
organ donation and transplantation globally.23,24 This new epidemic 
has overwhelmed healthcare resources in some regions and forced 
rationing of care, including Intensive Care Unit (ICU) beds and venti-
latory supports. As a consequence, organ donation and transplanta-
tion have been reduced in many countries. Overall, the progression 
of disease has varied but appears to be more rapid in immunocom-
promised hosts with greater rates of ICU admission and death.25- 28
All transplantation societies strongly recommend universal 
screening (nucleic acid testing [NAT]) of potential deceased organ 
donors before procurement.29 Donors with positive SARS- CoV- 2 
testing or donors with exposure risk criteria regardless of labora-
tory finding are generally excluded by most transplant organizations. 
Transmission from infected donors to immunosuppressed recipients 
has been recently described with lung transplantation.7,14,15,30
In both cases, the donor tested negative for SARS- CoV- 2 with 
upper respiratory tract sampling for nucleic acid testing, however, 
BAL in case 1 and bronchial wash in case 2 tested positive immedi-
ately after transplantation.14,15 Only lungs were transplanted from 
the first donor while the second donated the kidneys and the liver 
too. No transmission occurred to two kidney recipients (one had pre-
vious COVID- 19 vaccine and one had previous COVID- 19 infection) 
and one liver recipient. SARS- CoV- 2 has not been detected from 
liver tissue; SARS- CoV- 2 has only been detected from cardiac tissue 
in one patient with severe cardiac dysfunction, who would not be a 
candidate for donation.8
In Italy more than 4 million COVID- 19 cases have been reported 
by the end of May 2021 and about 260 000 are still positive. In order 
to maintain organ transplantation for lifesaving organs, in November 
2020 the CNT decided to allow the use of livers and hearts from 
donors with active SARS- CoV- 2 infection, documented by positive 
NAT testing in NPS or BAL at the time of donor evaluation. Antibody 
testing against SARS- CoV- 2 is not required by the Italian rules for 
deceased organ donor evaluation and no decision is taken based on 
their presence or not. However, IgG anti- SARS- CoV- 2 were tested in 
8 of 10 donors but the results were available only after the transplant 
procedures and did not influence in any way the use of the organs. 
As expected, seven of eight tested donors resulted anti- SARS- CoV- 2 
IgG negative. This is consistent with the median time required for 
developing a detectable serological response31 and supports the hy-
pothesis of an early infection of the donors, most of them died for 
causes unrelated to COVID- 19.
These organs can be transplanted into informed recipients with 
ongoing or resolved COVID- 19. Candidates with recent COVID- 19 
are in fact very likely protected by natural immunity and we as-
sumed that there was a very low risk of SARS- CoV- 2 transmission. 
Convalescent individuals from COVID- 19 have in fact a significantly 
lower risk of reinfection.32,33
Starting from November 2020 to May 2021, 19 organs (17 livers 
and 2 hearts) from SARS- CoV- 2 positive donors have been trans-
planted in Italy in recipients with ongoing or past COVID- 19. In the 
present paper we report the outcome of the first 10 LTs with at least 
5 months of follow- up. Only two recipients had a positive molecular 
test on NPS at the time of organ transplantation. Case 5 with a history 
of COVID- 19 in early November 2020, was relisted after two negative 
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NPS; just before transplantation he had indeterminate SARS- CoV- 2 
RNA in NPS but positive in BAL. This patient at the end of LT, was 
transferred to a COVID- dedicated ICU, where BAL confirmed to be 
positive for SARS- CoV- 2 RNA on POD 1 and 3. However, three con-
secutive NPS tested negative on POD 3, 4, and 7. The second recip-
ient (case 9) had a history of asymptomatic COVID- 19 in November 
2020 and high cycle threshold (Ct) at the time of liver transplantation 
(gene E Ct = 24; gene S Ct = 27; gene N Ct = 24),22 whose significance 
in terms of viral infectivity is controversial.
Testing for antibodies against SARS- CoV- 2 just before LT was 
positive in 8 of the 10 recipients and the in vitro viral neutralizing 
capacity of sera was ascertained in 5 of the 7 cases in which it was 
investigated, confirming, as expected, the presence of a potential 
protective immunity related to the recent SARS- CoV- 2 infection 
in most of the patients. In addition, testing for SARS- CoV- 2 on do-
nors’ liver biopsy before transplantation was negative in nine of nine 
tested donors suggesting a very low risk of transmission with LT. 
Only one recipient (case 9), who tested positive at the time of LT 
remained persistently positive up to 21 days after transplantation 
but with very high Ct.22 None of the remaining recipients was found 
to be positive for SARS- CoV- 2 during the follow- up.
Immunosuppression regimen remained unchanged, according to 
each Center standard protocol and no anti- SARS CoV- 2 therapy was 
used after LT.
The study has limitations mostly due to the small number of pa-
tients and the different methods used to assess the immunological 
status of the recipients. In addition, it is unclear if the lack of transmis-
sion was due to the immune protection of the recipients or to the lack 
of replicating virus in the liver grafts. However, despite the small num-
ber of cases we believe that transplanting livers from donors with pos-
itive SARS- CoV- 2 in upper and/or lower respiratory tract, in informed 
candidates with immunity due to past COVID- 19, might contribute to 
safely increase the donor pool during the COVID- 19 pandemic.
The increasing number of vaccinated candidates might allow the 
use of organs from donors with active COVID- 19 in recipients with 
prior vaccination. To date there are no correlates of antibody response 
and protection against SARS- CoV- 2 infection and therefore we did not 
consider vaccination sufficient to guarantee protection. Furthermore, 
it is well known that patients with chronic liver disease have a poor 
response to vaccines, including anti- COVID- 19 vaccines34 and there-
fore the use of these organs for vaccinated recipients is something 
that needs to be explored. In addition, the growing number of variants 
which may evade the individual natural or vaccine induced immunity is 
one of the major challenges we have to face in the near future. Finally, 
our results and the current limited published evidence suggest that 
organs from donors with active COVD- 19 could also be used for non- 
immune recipients, in particular for recipients at high risk for mortality 
on the waitlist. However larger studies are needed to confirm these 
results before recommending this possibility.
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